Clinical Implications of Extracellular HMGA1 in Breast Cancer.
cancer secretome
high mobility group A1 (HMGA1)
receptor for advanced glycation end products (RAGE)
triple-negative breast cancer (TNBC)
tumor biomarkers
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Nov 2019
26 Nov 2019
Historique:
received:
23
10
2019
revised:
19
11
2019
accepted:
22
11
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
21
4
2020
Statut:
epublish
Résumé
The unconventional secretion of proteins is generally caused by cellular stress. During the tumorigenesis, tumor cells experience high levels of stress, and the secretion of some theoretically intracellular proteins is activated. Once in the extracellular space, these proteins play different paracrine and autocrine roles and could represent a vulnerability of cancer. One of these proteins is the high mobility group A1 (HMGA1), which is frequently overexpressed in tumors and presents a low expression in normal adult tissues. We have recently described that HMGA1 establishes an autocrine loop in invasive triple-negative breast cancer (TNBC) cells. The secretion of HMGA1 and its binding to the receptor for advanced glycation end products (RAGE) mediates the migration, invasion, and metastasis of TNBC cells and predicts the onset of metastasis in these patients. In this review, we summarized different strategies to exploit the novel tumorigenic phenotype mediated by extracellular HMGA1. We envisioned future clinical applications where the association between its change in subcellular localization and breast cancer progression could be used to predict tumor aggressiveness and guide treatment decisions. Furthermore, we proposed that targeting extracellular HMGA1 as monotherapy using monoclonal antibodies, or in combination with chemotherapy and other targeted therapies, could bring new therapeutic options for TNBC patients.
Identifiants
pubmed: 31779212
pii: ijms20235950
doi: 10.3390/ijms20235950
pmc: PMC6928815
pii:
doi:
Substances chimiques
AGER protein, human
0
HMGA1 protein, human
0
Receptor for Advanced Glycation End Products
0
HMGA1a Protein
124544-67-8
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Susan G. Komen
ID : CCR15333737
Pays : United States
Références
Mol Med. 2008 Jul-Aug;14(7-8):476-84
pubmed: 18431461
Biochem Biophys Res Commun. 2003 Jul 25;307(2):375-81
pubmed: 12859967
N Engl J Med. 2019 Mar 7;380(10):987-988
pubmed: 30855757
Anat Rec (Hoboken). 2018 Jun;301(6):1061-1067
pubmed: 29316384
Pancreatology. 2012 Jul-Aug;12(4):372-9
pubmed: 22898640
Front Immunol. 2015 Aug 18;6:422
pubmed: 26347745
Mol Cell Proteomics. 2013 May;12(5):1046-60
pubmed: 23268930
Urol Oncol. 2019 Nov;37(11):810.e7-810.e15
pubmed: 31053526
Trends Biochem Sci. 2011 Dec;36(12):625-32
pubmed: 22019011
J Pathol. 2003 Aug;200(5):589-95
pubmed: 12898594
Gynecol Oncol. 2016 Jun;141(3):580-587
pubmed: 27001612
Oncogene. 2017 Mar;36(11):1559-1572
pubmed: 27669433
Neurology. 2014 Apr 29;82(17):1536-42
pubmed: 24696507
J Biomed Biotechnol. 2011;2011:567305
pubmed: 22007144
Cancer Res. 1996 Apr 15;56(8):1896-901
pubmed: 8620511
Genes (Basel). 2019 May 15;10(5):
pubmed: 31096664
Pathol Oncol Res. 2012 Apr;18(2):293-8
pubmed: 21953322
J Cell Mol Med. 2019 Apr;23(4):2293-2302
pubmed: 30614613
Biochim Biophys Acta. 2013 Nov;1834(11):2242-58
pubmed: 23376433
Oncol Lett. 2016 Jan;11(1):293-298
pubmed: 26870206
Cancer Manag Res. 2019 Jan 10;11:637-649
pubmed: 30666160
Mol Cell Biochem. 2015 Jun;404(1-2):251-7
pubmed: 25772486
Clin Cancer Res. 2004 Feb 15;10(4):1401-8
pubmed: 14977843
Oncogene. 1996 Dec 5;13(11):2439-46
pubmed: 8957086
Melanoma Res. 2003 Feb;13(1):45-9
pubmed: 12569284
J Proteomics. 2013 Dec 16;95:55-65
pubmed: 23770383
Science. 1999 Jul 9;285(5425):248-51
pubmed: 10398600
PLoS One. 2014 Nov 17;9(11):e111885
pubmed: 25401330
Biochim Biophys Acta. 2001 May 28;1519(1-2):13-29
pubmed: 11406267
Oncol Rep. 2009 Sep;22(3):535-9
pubmed: 19639200
Neoplasia. 2016 Dec;18(12):724-731
pubmed: 27855356
J Biol Chem. 1991 Sep 5;266(25):16722-9
pubmed: 1885601
Int J Surg. 2015 Dec;24(Pt A):39-44
pubmed: 26537313
Adv Exp Med Biol. 2019;1152:401-411
pubmed: 31456196
Cancer Res. 2018 Apr 15;78(8):1890-1897
pubmed: 29618461
Breast Cancer Res Treat. 2013 Nov;142(2):297-309
pubmed: 24177755
Annu Rev Med. 2018 Jan 29;69:349-364
pubmed: 29106804
J Exp Clin Cancer Res. 2018 Apr 3;37(1):77
pubmed: 29615080
Int J Mol Med. 2015 Mar;35(3):693-701
pubmed: 25572132
Mol Med Rep. 2017 Feb;15(2):534-542
pubmed: 28000891
Horm Cancer. 2018 Oct;9(5):295-325
pubmed: 29987748
Nature. 2000 May 18;405(6784):354-60
pubmed: 10830965
PLoS One. 2014 Jan 27;9(1):e86903
pubmed: 24475194
Am J Pathol. 2009 Oct;175(4):1675-85
pubmed: 19729480
Dev Cell. 2019 May 6;49(3):361-374
pubmed: 31063755
Oncotarget. 2014 May 30;5(10):3220-33
pubmed: 24952599
Prog Cell Cycle Res. 1995;1:339-49
pubmed: 9552376
Structure. 2010 Oct 13;18(10):1342-52
pubmed: 20947022
Cancer Sci. 2006 Oct;97(10):1061-9
pubmed: 16984379
J Exp Clin Cancer Res. 2019 Jul 16;38(1):313
pubmed: 31311575
Cancer Res. 2015 Mar 15;75(6):974-85
pubmed: 25572331
PLoS One. 2013 May 02;8(5):e63419
pubmed: 23658826
Nat Commun. 2017 Apr 28;8:15008
pubmed: 28452345
Exp Cell Res. 2005 Jul 15;307(2):388-401
pubmed: 15893306
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):216-229
pubmed: 29518471
Oncotarget. 2018 Jan 10;9(11):9963-9974
pubmed: 29515783
Eur J Clin Invest. 2013 Mar;43(3):286-91
pubmed: 23410002
Cancer Cell Int. 2019 Jun 14;19:164
pubmed: 31249473
Proteomics Clin Appl. 2015 Apr;9(3-4):348-57
pubmed: 25418557
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
J Immunol. 2006 Dec 1;177(11):7889-97
pubmed: 17114460
J Cell Sci. 2000 Feb;113 ( Pt 4):611-20
pubmed: 10652254
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Eur J Cancer. 2013 Aug;49(12):2643-53
pubmed: 23726265
Int J Mol Sci. 2019 Oct 07;20(19):null
pubmed: 31591367
Nat Rev Drug Discov. 2009 Dec;8(12):935-48
pubmed: 19949400
Front Immunol. 2019 Feb 27;10:333
pubmed: 30873179
Sci Rep. 2017 Sep 18;7(1):11768
pubmed: 28924209
Adv Exp Med Biol. 2019;1136:57-69
pubmed: 31201716
Drugs. 2014 Oct;74(16):1891-1925
pubmed: 25315029
Leuk Lymphoma. 2016 Nov;57(11):2681-4
pubmed: 26952843
World J Gastroenterol. 2015 Mar 21;21(11):3256-65
pubmed: 25805932
Oncotarget. 2013 Aug;4(8):1293-308
pubmed: 23945276
Biochim Biophys Acta. 2009 Jun;1793(6):993-1007
pubmed: 19121341
Oncol Lett. 2018 Jun;15(6):8303-8310
pubmed: 29928320
BMC Urol. 2019 Jun 13;19(1):53
pubmed: 31196036
Cancer Res. 1997 Jun 1;57(11):2276-80
pubmed: 9187132
Nat Med. 1995 Jan;1(1):27-31
pubmed: 7584949
J Clin Invest. 2012 Apr;122(4):1377-92
pubmed: 22406537
Nat Commun. 2014 Oct 28;5:5256
pubmed: 25348021
Nature. 2015 Jun 4;522(7554):106-110
pubmed: 26017313
Int J Oncol. 2018 Oct;53(4):1481-1492
pubmed: 30066846
Ann Oncol. 2009 Oct;20(10):1639-46
pubmed: 19549711
J Cell Mol Med. 2016 May;20(5):825-35
pubmed: 26928771
Circ Res. 2010 Mar 19;106(5):842-53
pubmed: 20299674
Clin Breast Cancer. 2017 Oct;17(6):441-452.e2
pubmed: 28533055
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Oncotarget. 2017 May 16;8(38):64534-64550
pubmed: 28969092
J Proteome Res. 2009 Mar;8(3):1489-503
pubmed: 19199430
EMBO Rep. 2004 Aug;5(8):825-30
pubmed: 15272298
Oncotarget. 2016 Apr 19;7(16):21825-39
pubmed: 26968810
J Clin Oncol. 2011 Nov 10;29(32):4286-93
pubmed: 21990397
Cancer Res. 2010 Jan 15;70(2):436-9
pubmed: 20068164
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
Adv Anat Pathol. 1999 Sep;6(5):237-46
pubmed: 10472377
Oncogene. 1995 Apr 6;10(7):1307-14
pubmed: 7731681
J Proteome Res. 2014 Aug 1;13(8):3706-3721
pubmed: 24897304
Clin Cancer Res. 2018 Dec 15;24(24):6367-6382
pubmed: 30135148
Nature. 2015 Apr 16;520(7547):368-72
pubmed: 25807485
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Clin Cancer Res. 2013 Aug 1;19(15):4046-57
pubmed: 23723299
Hum Pathol. 2018 Apr;74:156-163
pubmed: 29320752
J Clin Pathol. 2016 Feb;69(2):117-21
pubmed: 26251519
J Transl Med. 2009 Mar 17;7:17
pubmed: 19292913
J Alzheimers Dis. 2019;67(3):779-794
pubmed: 30689575
Mod Pathol. 2008 Jun;21(6):756-63
pubmed: 18376386
J Am Soc Nephrol. 2011 Mar;22(3):416-25
pubmed: 21335516
Breast Cancer Res Treat. 2017 Feb;162(1):127-137
pubmed: 28058579
Nat Rev Cancer. 2007 Dec;7(12):899-910
pubmed: 18004397
Cancer Lett. 2019 May 28;450:1-13
pubmed: 30776481
Oncogene. 1998 Jul 2;16(26):3387-96
pubmed: 9692546
Pathol Res Pract. 2017 Aug;213(8):915-921
pubmed: 28651933
Int J Mol Sci. 2013 Apr 11;14(4):7959-78
pubmed: 23579957
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Cell Death Dis. 2019 Feb 12;10(2):131
pubmed: 30755600
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Drugs. 2019 Jul;79(11):1217-1230
pubmed: 31254268
Cancer Treat Rev. 2018 Nov;70:190-198
pubmed: 30243063
Cancer Lett. 2016 Jun 1;375(2):245-255
pubmed: 26952810
Cell Rep. 2019 Jul 16;28(3):773-791.e7
pubmed: 31315054
Sci Transl Med. 2019 Mar 20;11(484):
pubmed: 30894502
BMC Cancer. 2010 Sep 16;10:496
pubmed: 20846416
EMBO J. 2003 Oct 15;22(20):5551-60
pubmed: 14532127
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Oncologist. 2013;18(2):123-33
pubmed: 23404817